Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.56 |
| ▸ | MGLL | Q99685 | 5/20 | 0.55 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219256 | 1.00 | HSD11B1 (0.56) | HSD11B1MGLLMAPK7ACACBCACNA1B | |
| SCHEMBL2219227 | 0.90 | MGLL (0.57) | HSD11B1MGLLALDH1A1L3MBTL1KDM4E | |
| SCHEMBL2219230 | 0.90 | MGLL (0.57) | HSD11B1MGLLALDH1A1L3MBTL1KDM4E | |
| SCHEMBL1578443 | 0.86 | UBE2M (0.56) | HSD11B1MGLLACACBCACNA1BKMT2A | |
| SCHEMBL1578447 | 0.86 | UBE2M (0.56) | HSD11B1MGLLACACBCACNA1BKMT2A | |
| SCHEMBL12515930 | 0.85 | RBP4 (0.50) | HSD11B1MGLLALDH1A1MEN1KMT2A | |
| SCHEMBL2219637 | 0.85 | ALDH1A1 (0.61) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL27976746 | 0.85 | RBP4 (0.50) | HSD11B1MGLLALDH1A1MEN1KMT2A | |
| SCHEMBL2219630 | 0.85 | ALDH1A1 (0.61) | HSD11B1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL2217297 | 0.84 | MGLL (0.58) | HSD11B1MGLLALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | HSD11B1 3190/4885MGLL 692/4885MAPK7 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.